10 April 2018 - Purdue Pharma (Canada) and Medical Developments International Limited, announce today that Penthrox, a low dose methoxyflurane, has been granted marketing authorisation by Health Canada for the short-term relief of moderate to severe acute pain, associated with trauma or interventional medical procedures, in conscious adult patients.

Penthrox (methoxyflurane) is an effective, fast-acting, inhaled analgesic product which is not classified as an opioid. The treatment is self-administered by the patient under the supervision of a trained healthcare practitioner, including nurses and paramedics.

Penthrox is approved for marketing in more than 20 countries, including Australia, UK, Ireland, France, Belgium, Sweden, Singapore and South Africa.

Read Purdue Pharma press release